Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21-Reference-Cited by-同舟云学术

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

Published:2014-04 Issue:4 Volume:9 Page:506-511
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lim Sung Hee,Lee Ji Yun,Sun Jong-Mu,Ahn Jin Seok,Park Keunchil,Ahn Myung-Ju

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

2. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected];Fukuoka;J Clin Oncol,2003

3. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer);Thatcher;Lancet,2005

4. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study;Chang;J Thorac Oncol,2006

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of tumor abnormal protein expression and epidermal growth factor receptor mutation status in non-small cell lung cancer;Discover Oncology;2024-07-09

2. Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations;Oncology Letters;2024-05-01

3. Value of multi‐center ¹⁸F‐FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma;Medical Physics;2024-01-29

4. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma;Journal of Cancer Research and Therapeutics;2024-01-22

5. Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients;Biomedicines;2023-10-28